potential COVID-19 treatments - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.60 [0.45, 0.79]< 10%13 studies (13/-)100.0 %highlow lowcrucial-
death or transfer to ICU 0.89 [0.59, 1.34]< 146%2 studies (2/-)71.8 %highnot evaluable lowcrucial-
deaths 0.75 [0.64, 0.88]< 10%37 studies (37/-)100.0 %highcritical lowcrucial-
deaths (time to event analysis only) 0.68 [0.43, 1.08]< 10%4 studies (4/-)95.0 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.74 [0.55, 1.00]< 161%17 studies (17/-)97.5 %highlow lowimportant-
clinical improvement 1.24 [1.04, 1.47]> 140%15 studies (15/-)99.3 %highlow lowimportant-
clinical improvement (14-day) 1.17 [0.93, 1.47]> 135%9 studies (9/-)91.6 %some concernnot evaluable moderateimportant-
clinical improvement (21-day) 2.09 [0.04, 119.96]> 10%1 study (1/-)63.7 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.34 [1.10, 1.62]> 146%5 studies (5/-)99.8 %some concernserious moderateimportant-
clinical improvement (7-day) 1.24 [0.99, 1.55]> 165%10 studies (10/-)96.7 %highcritical lowimportant-
clinical improvement (time to event analysis only) 1.21 [1.03, 1.41]> 148%9 studies (9/-)99.1 %highnot evaluable lowimportant-
death or ventilation 0.75 [0.63, 0.88]< 10%5 studies (5/-)100.0 %some concernnot evaluable moderateimportant-
hospital discharge 1.21 [0.97, 1.51]> 146%7 studies (7/-)95.6 %highserious lowimportant-
hospitalization 0.46 [0.06, 3.45]< 128%2 studies (2/-)77.4 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.81 [0.54, 1.21]< 119%14 studies (14/-)85.0 %highcritical lowimportant-
mechanical ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 10%1 study (1/-)98.2 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 1.82 [0.95, 3.51]> 139%4 studies (4/-)96.4 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.40 [0.02, 6.97]> 177%3 studies (3/-)26.9 %highnot evaluable lowimportant-
viral clearance 1.32 [1.02, 1.71]> 166%16 studies (16/-)98.2 %highcritical lowimportant-
viral clearance (time to event analysis only) 1.05 [0.80, 1.39]> 160%6 studies (6/-)64.1 %highnot evaluable lowimportant-
viral clearance by day 14 0.98 [0.18, 5.42]> 194%9 studies (9/-)49.0 %highnot evaluable lowimportant-
viral clearance by day 7 1.29 [1.01, 1.65]> 170%12 studies (12/-)97.8 %highlow lowimportant-
ICU admission 0.93 [0.68, 1.26]< 10%8 studies (8/-)68.3 %highnot evaluable lownon important-
recovery 1.13 [0.98, 1.31]> 10%3 studies (3/-)95.4 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.74 [0.53, 1.04]< 10%15 studies (15/-)96.0 %highcritical lowimportant-
acute kidney injury 1.18 [0.44, 3.18]< 10%1 study (1/-)37.2 %some concernnot evaluable moderatenon important-
adverse events 1.89 [1.39, 2.58]< 165%19 studies (19/-)0.0 %